New cancer drug GEN1106 enters first human tests

NCT ID NCT07416123

First seen Feb 18, 2026 · Last updated Jun 15, 2026 · Updated 18 times

Summary

This early-stage trial tests a new drug, GEN1106, in about 103 people with solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants receive the active drug, and the study lasts about 17 months per person, including treatment and follow-up.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Carolina Urologic Research Center

    RECRUITING

    Myrtle Beach, South Carolina, 29572, United States

  • National Cancer Center Hospital

    RECRUITING

    Chuo Ku, Tokyo, 104-0045, Japan

  • START New York Long Island LLC

    RECRUITING

    Lake Success, New York, 11042, United States

  • South Texas Accelerated Research Therapeutics

    RECRUITING

    San Antonio, Texas, 78229, United States

Conditions

Explore the condition pages connected to this study.